



NEW LISTING ON RAMQ¹

LATUDA[®] (20 mg, 40 mg, 60 mg, 80 mg, 120 mg) is now available through the Régie de l'assurance maladie du Québec (RAMQ) as médicaments d'exception for THE MANAGEMENT OF DEPRESSIVE EPISODES OF BIPOLAR I DISORDER²



LATUDA is also available through the Régie de l'assurance maladie du Québec (RAMQ) as médicaments d'exception for the treatment of the manifestations of schizophrenia.

LATUDA is indicated for monotherapy or as adjunctive therapy with lithium or valproate for the acute management of depressive episodes associated with bipolar I disorder and for the management of the manifestations of schizophrenia¹

Please consult the product monograph at www.sunovion.ca/monographs/latuda.pdf for contraindications, warnings, precautions, adverse reactions, drug interactions, and dosing information, which have not been discussed in this piece. The product monograph is also available by calling Sunovion Medical Information at 1-866-260-6291.

1. RAMQ is the Official Mark of the Régie de l'assurance maladie du Québec.
2. RAMQ Liste des médicaments, Oct 3, 2016 (http://www.ramq.gouv.qc.ca/SiteCollectionDocuments/liste_med/liste_med_2016_10_03_en.pdf)
3. LATUDA Product Monograph, Sunovion Pharmaceuticals Canada Inc., April 28, 2016



LATUDA[®] is a trademark of Sumitomo Dainippon Pharma Co., Ltd.
© 2016 Sunovion Pharmaceuticals Canada Inc. All rights reserved